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Invasive candidiasis is a serious complication in the intensive care unit (ICU), with high morbidity and mortality up to 90% in patients with septic shock (1). The epidemiology of Candida infections is continuously changing, also 
in relation to the timing of acquisition, with increasing data on early diagno-
sis after ICU admission (2, 3). By a clinical point of view, early and appropri-
ate treatment is the key for a significant reduction in mortality and, by con-
verse, up to 70% of critically ill patients receive systemic antifungal therapy 
although they have no documented invasive fungal infection, suggesting an 
urgent need for antifungal stewardship strategies (4-11). However, several di-
agnostic strategies that have benn studied for early and appropriate treatment 
of invasive candidiasis have been studied and are hereafter briefly discussed.
In the early 1990s, Pittet et al. (9) defined the Candida Colonization Index 
(CI) as the daily determination as the ratio of the number of distinct body 
sites colonized with identical strains over the total number of body sites test-
ed in 29 patients at high risk of Candida infection. At that time, the proposed 
colonization index had high positive predictive values (66-100%).  However, 
the CI has not been validated in large multicenter trials and its validity has 
been suggested almost exclusively in surgical patients (7-9, 12). In the setting 
of intra-abdominal candidiasis (IAC), multifocal colonization may not be re-
quired to significantly affect the peritoneum from an abdominal source, espe-
cially with suture dehiscence and anastomotic leakages (13). Moreover, the CI 
is expensive and time consuming, and further critics are represented by the low 
accuracy (11), such as? The failure to substantial guide empiric treatment (14) 
and the evidence of a lower use of antifungals when clinicians were not pro-
vided with CI (15, 16).
The Candida Score (CS) combined in a predictive clinical the results of a 
prospective cohort study, where surgery, multifocal colonization, total paren-
teral nutrition and severe sepsis predicted invasive candidiasis, with 81% of 
sensitivity and 74% of specificity and a had negative predictive value (NPV) 
of 98% (17). The accuracy of a CS ≥3 was greater than that of a CI ≥0.5. 
Questions on practical use of CS were quickly appreciated: has the financial 
burden of the antifungal treatment increased? Is the acute change of CS more 
important than the score itself?
Other Authors proposed a predictive rule for the likelihood of Candida in-
volvement, especially in peritonitis, based on four risk factors: female sex, 
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upper gastrointestinal injury or surgery, cardiovascular failure and 
previous antimicrobial therapy (18). With ≥3 risk factors the pre-
diction of invasive intrabdominal candidiasis (IAC) had a sensitiv-
ity, specificity, positive predictive value (PPV) and NPV of 84%, 
50%, 67% and 72%, respectively. Ostrosky-Zeichner et al. created 
a clinical prediction rule to identify patients at risk of invasive can-
didiasis including the parameters of ICU  stay ≥4 days, mechanical 
ventilation, central venous catheter and broad spectrum antibiotics 
plus an additional risk factor (19).
However, despite a progressive improvement in the accuracy of 
these rules and a better PPV compared to CI and CS, so far no 
studies validated their systematic clinical usefulness (20). CI, CS 
and other predictive rules have been specifically developed by using 
their PPV for the early identification of high-risk patients, but their 
NPV is definitely much more significant (21). The low level of evi-
dence attributed by experts to the risk-based strategies in consensus 
guidelines may be explained by the laborious nature of the clinical 
use and the lack of solid clinical data (22-24).
An innovative way to diagnostic approach of these infections is by 
utilizing biomarkers in addition to CS, CI and predictive rules in 
order to guide antifungal therapy (17, 25). Although blood cul-
tures are still considered the gold standard for diagnosis, it has been 
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Figure 1. Algorithm of antifungal treatment possible de-escalation strategies in ICU patients [Modified from Eggimann et al. (31)]
TNP: total parenteral nutrition; BDG: beta-D-glucan; AF: antifungal; + : positive (>80 pg/mL); -: negative
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shown that they are negative in up to 50% of cases (26). Thus, 
non-culture diagnostic techniques based on serological biomark-
ers detecting fungal cell components and/or antibodies directed 
against these components have been investigated (26). All these 
diagnostic tests may diagnose candidiasis earlier than clinical or 
culture-based measures.
Amongst biomarkers, mannan antigen and antigen-antibodies 
complex showed a higher sensitivity and specificity when combined 
together (27). In a meta-analysis of 14 studies, seven of which were 
performed in non-neutropenic critically ill patients, the sensitivity 
and specificity of mannan and anti-mannan IgG were 58% and 
93%, and 59% and 83%, respectively. Values for the combined 
assay were 83 and 86%, with best performances for C. albicans, C. 
glabrata, and C. tropicalis infection (27).
The 1,3-beta-D-glucan (BG) is a fungal cell wall antigen that 
can be detected in blood of patients with a sensitivity of 56-93% 
and a specificity of 71-100% for candidiasis (28). In a recent me-
ta-analysis of 11 studies, the sensitivity and specificity of BG for 
the diagnosis of IC were 57-97% and 56-93%, respectively (28). 
Thanks to its high NPV, BG is potentially useful for the therapy 
decision-making process and discontinuing of empirical antifun-
gal therapy, a practice known as de-escalation and reinforced by 
the most recent guidelines (23, 24). An integrated strategy with 
BG and CS helped to withhold or discontinue treatment, saving 
precious money without increasing mortality in 198 severely ill pa-
tients admitted to ICU with sepsis and a CS>3 (29). In patients 
with suspected IAC, Tissot et al. compared the diagnostic accuracy 
of BG to CS and CI in high-risk surgical ICU patients (abdominal 
surgery or acute pancreatitis and ICU stay ≥72h) (30). The results 
showed that in patients with recurrent GI tract perforation, BG 
≥80 pg/mL discriminated IAC from colonization with 72% PPV 
and 80% NPV and was superior to CI and CS (30). Moreover, BG 
determination preceded microbiological documentation of IAC 
with intra-abdominal cultures and start of antifungal therapy by 
a median of five and six days, respectively, suggesting a potential 
role on a pre-emptive basis (30). Also, BG kinetics reflected sever-
ity of infection, response to antifungal therapy and clinical out-
come, suggesting that BG can be used as a reliable marker to stop or 
de-escalate antifungal treatment (Figure 1) (31). Molecular-based 
diagnostic tests can potentially be very sensitive in detecting an in-
vasive fungal infection and may provide results more rapidly than 
standard diagnostic procedures, but so far few data are available 
and they are not yet recommended, because of the heterogeneity 
of the available results, the lack of reliable reference standards and 
differences in techniques (26, 32, 33). 
In conclusion, we have multiple predictive tools for invasive candi-
diasis, which may suggest how and when to start empiric antifun-
gal treatment in critically ill patients. However, since the effect of 
these common antifungal strategies in non-neutropenic critically ill 
patients on mortality was criticized (34, 35), it may be  reasonable 
to use these strategies acknowledging that, from an antifungal stew-
ardship approach, de-escalation is the key! 
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